| Message: | Product Name: Cyproterone Acetate
CAS: 427-51-0
EINECS: 207-048-3
MF: C24H29ClO4
MW: 416.94
Assay: 98%
Appearance: White Crystalline Powder
Cyproterone acetate sometimes abbreviated as CPA, and sold under brand names such as Androcur and Cyprostat, is a synthetic steroidal antiandrogen drug with additional progestogen and antigonadotropic properties. Its primary action is to suppress the activity of the androgen hormones such as testosterone and its more potent metabolite dihydrotestosterone (DHT) in the body, effects which it mediates via competitive antagonism of the androgen receptor and inhibition of enzymes in the androgen biosynthesis pathway. The main therapeutic indications of cyproterone acetate are prostate cancer, benign prostatic hyperplasia, priapism, hypersexuality (e.g., as a form of chemical castration), and other conditions in which androgen action maintains the disease process. In addition, it can also be used to treat acne and hirsutism in females, and is a common component in hormone therapy for transsexual women.
In addition to its antiandrogen properties, cyproterone acetate has weak progestogen activity (i.e., it acts like progesterone). Accordingly, it can be used to treat hot flashes, and is also a component of some combined oral contraceptive pills such as Dianette in the United Kingdom and Diane-35 in other countries such as Canada. It is called Dixi-35 in Chile. No form of cyproterone acetate is available in the United States.
Until the development of leuprorelin, cyproterone acetate was one of the few drugs used to treat precocious puberty. It was also used in animal experimentation to investigate the actions of androgens in fetal sexual differentiation.
|
my account
